Reduction of serum IGF-I levels in patients affected with monoclonal gammopathies of undetermined significance or multiple myeloma. Comparison with bFGF, VEGF and K-ras gene mutation

Claudia Greco, Gaetano Vitelli, Giuseppe Vercillo, Rosa Vona, Diana Giannarelli, Isabella Sperduti, Francesco Pisani, Ettore Capoluongo, Maria Concetta Petti, Franco Ameglio

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background. Serum levels of IGF-I in patients affected with multiple myeloma (MM) have been scarcely studied. The present study is aimed to explore this point comparing 55 healthy subjects, 71 monoclonal gammopaties of uncertain significance (MGUS) and 77 overt MM patients. In the same subjects, basic FGF and VEGF, have been detected. All three mediators were analyzed in function of K-ras mutation and melphalan response. Concerning IGF-I, two representative monitoring examples have also been added. Methods. Cytokine determinations were performed by commercially available ELISA kits, while K12-ras mutation was investigated on genomic DNA isolated from bone marrow cell specimens by RFLP-PCR assay. Results. Significant reductions of IGF-I levels were observed in MGUS and MM as compared with healthy controls. In addition, MM subjects showed significantly decreased serum IGF-I levels than MGUS. Conversely, increasing levels were observed for bFGF and VEGF, molecules significantly correlated. A multivariate analysis corrected for age and gender confirmed the significant difference only for IGF-I values (P = 0.01). K12-ras mutation was significantly associated with malignancy, response to therapy and with significantly increased serum bFGF levels. Conclusion. IGF-I reduction in the transition: ControlsMGUSMM and changes observed over time suggest that IGF-I should be furtherly studied in future clinical trials as a possible monitoring marker for MM.

Original languageEnglish
Article number35
JournalJournal of Experimental and Clinical Cancer Research
Volume28
Issue number1
DOIs
Publication statusPublished - 2009

Fingerprint

Monoclonal Gammopathy of Undetermined Significance
ras Genes
Multiple Myeloma
Insulin-Like Growth Factor I
Vascular Endothelial Growth Factor A
Mutation
Serum
Melphalan
Bone Marrow Cells
Restriction Fragment Length Polymorphisms
Healthy Volunteers
Multivariate Analysis
Enzyme-Linked Immunosorbent Assay
Clinical Trials
Cytokines
Polymerase Chain Reaction
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Reduction of serum IGF-I levels in patients affected with monoclonal gammopathies of undetermined significance or multiple myeloma. Comparison with bFGF, VEGF and K-ras gene mutation. / Greco, Claudia; Vitelli, Gaetano; Vercillo, Giuseppe; Vona, Rosa; Giannarelli, Diana; Sperduti, Isabella; Pisani, Francesco; Capoluongo, Ettore; Petti, Maria Concetta; Ameglio, Franco.

In: Journal of Experimental and Clinical Cancer Research, Vol. 28, No. 1, 35, 2009.

Research output: Contribution to journalArticle

Greco, Claudia ; Vitelli, Gaetano ; Vercillo, Giuseppe ; Vona, Rosa ; Giannarelli, Diana ; Sperduti, Isabella ; Pisani, Francesco ; Capoluongo, Ettore ; Petti, Maria Concetta ; Ameglio, Franco. / Reduction of serum IGF-I levels in patients affected with monoclonal gammopathies of undetermined significance or multiple myeloma. Comparison with bFGF, VEGF and K-ras gene mutation. In: Journal of Experimental and Clinical Cancer Research. 2009 ; Vol. 28, No. 1.
@article{f4da30a388874ed7b15f844d7b2ca046,
title = "Reduction of serum IGF-I levels in patients affected with monoclonal gammopathies of undetermined significance or multiple myeloma. Comparison with bFGF, VEGF and K-ras gene mutation",
abstract = "Background. Serum levels of IGF-I in patients affected with multiple myeloma (MM) have been scarcely studied. The present study is aimed to explore this point comparing 55 healthy subjects, 71 monoclonal gammopaties of uncertain significance (MGUS) and 77 overt MM patients. In the same subjects, basic FGF and VEGF, have been detected. All three mediators were analyzed in function of K-ras mutation and melphalan response. Concerning IGF-I, two representative monitoring examples have also been added. Methods. Cytokine determinations were performed by commercially available ELISA kits, while K12-ras mutation was investigated on genomic DNA isolated from bone marrow cell specimens by RFLP-PCR assay. Results. Significant reductions of IGF-I levels were observed in MGUS and MM as compared with healthy controls. In addition, MM subjects showed significantly decreased serum IGF-I levels than MGUS. Conversely, increasing levels were observed for bFGF and VEGF, molecules significantly correlated. A multivariate analysis corrected for age and gender confirmed the significant difference only for IGF-I values (P = 0.01). K12-ras mutation was significantly associated with malignancy, response to therapy and with significantly increased serum bFGF levels. Conclusion. IGF-I reduction in the transition: ControlsMGUSMM and changes observed over time suggest that IGF-I should be furtherly studied in future clinical trials as a possible monitoring marker for MM.",
author = "Claudia Greco and Gaetano Vitelli and Giuseppe Vercillo and Rosa Vona and Diana Giannarelli and Isabella Sperduti and Francesco Pisani and Ettore Capoluongo and Petti, {Maria Concetta} and Franco Ameglio",
year = "2009",
doi = "10.1186/1756-9966-28-35",
language = "English",
volume = "28",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Reduction of serum IGF-I levels in patients affected with monoclonal gammopathies of undetermined significance or multiple myeloma. Comparison with bFGF, VEGF and K-ras gene mutation

AU - Greco, Claudia

AU - Vitelli, Gaetano

AU - Vercillo, Giuseppe

AU - Vona, Rosa

AU - Giannarelli, Diana

AU - Sperduti, Isabella

AU - Pisani, Francesco

AU - Capoluongo, Ettore

AU - Petti, Maria Concetta

AU - Ameglio, Franco

PY - 2009

Y1 - 2009

N2 - Background. Serum levels of IGF-I in patients affected with multiple myeloma (MM) have been scarcely studied. The present study is aimed to explore this point comparing 55 healthy subjects, 71 monoclonal gammopaties of uncertain significance (MGUS) and 77 overt MM patients. In the same subjects, basic FGF and VEGF, have been detected. All three mediators were analyzed in function of K-ras mutation and melphalan response. Concerning IGF-I, two representative monitoring examples have also been added. Methods. Cytokine determinations were performed by commercially available ELISA kits, while K12-ras mutation was investigated on genomic DNA isolated from bone marrow cell specimens by RFLP-PCR assay. Results. Significant reductions of IGF-I levels were observed in MGUS and MM as compared with healthy controls. In addition, MM subjects showed significantly decreased serum IGF-I levels than MGUS. Conversely, increasing levels were observed for bFGF and VEGF, molecules significantly correlated. A multivariate analysis corrected for age and gender confirmed the significant difference only for IGF-I values (P = 0.01). K12-ras mutation was significantly associated with malignancy, response to therapy and with significantly increased serum bFGF levels. Conclusion. IGF-I reduction in the transition: ControlsMGUSMM and changes observed over time suggest that IGF-I should be furtherly studied in future clinical trials as a possible monitoring marker for MM.

AB - Background. Serum levels of IGF-I in patients affected with multiple myeloma (MM) have been scarcely studied. The present study is aimed to explore this point comparing 55 healthy subjects, 71 monoclonal gammopaties of uncertain significance (MGUS) and 77 overt MM patients. In the same subjects, basic FGF and VEGF, have been detected. All three mediators were analyzed in function of K-ras mutation and melphalan response. Concerning IGF-I, two representative monitoring examples have also been added. Methods. Cytokine determinations were performed by commercially available ELISA kits, while K12-ras mutation was investigated on genomic DNA isolated from bone marrow cell specimens by RFLP-PCR assay. Results. Significant reductions of IGF-I levels were observed in MGUS and MM as compared with healthy controls. In addition, MM subjects showed significantly decreased serum IGF-I levels than MGUS. Conversely, increasing levels were observed for bFGF and VEGF, molecules significantly correlated. A multivariate analysis corrected for age and gender confirmed the significant difference only for IGF-I values (P = 0.01). K12-ras mutation was significantly associated with malignancy, response to therapy and with significantly increased serum bFGF levels. Conclusion. IGF-I reduction in the transition: ControlsMGUSMM and changes observed over time suggest that IGF-I should be furtherly studied in future clinical trials as a possible monitoring marker for MM.

UR - http://www.scopus.com/inward/record.url?scp=63849130567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63849130567&partnerID=8YFLogxK

U2 - 10.1186/1756-9966-28-35

DO - 10.1186/1756-9966-28-35

M3 - Article

C2 - 19284554

AN - SCOPUS:63849130567

VL - 28

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 1

M1 - 35

ER -